Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS5007 in Advanced Solid Tumors
NCT07622524Phase 1Recruiting
- Sponsor
- CStone Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Countries
- 2
01
Overview
Phase 1, open-label trial of CS5007 in solid tumor (2 arms), sponsored by CStone Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
CS5007
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07622524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622524.